We aimed to characterize the HMW by-products of a 2 + 1 trivalent bsAb heterodimer (2 + 1 CrossMAb) therapeutic product with two identical tumor-cell-specific targeting Fabs and one CD3-targeting Fab. Here, FANCB is linked to neoplasm.